Paramyxoviridae (e.g., Parainfluenza Virus, Respiratory Syncytial Virus, Rinderpest Virus, Sendai Virus, Canine Tracheobronchitis Virus, Turkey Rhinotracheitis Virus, Etc.) Patents (Class 424/211.1)
-
Publication number: 20090274727Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: ApplicationFiled: May 4, 2009Publication date: November 5, 2009Applicant: MEDIMMUNE, LLCInventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Patent number: 7595054Abstract: Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.Type: GrantFiled: November 30, 2007Date of Patent: September 29, 2009Assignee: Healthbanks Biotech Co., Ltd.Inventors: Chao-Wei Liao, Chung-Nan Weng, Hsiu-Kang Chang
-
Patent number: 7588770Abstract: The invention provides recombinant viruses comprising heterologous envelope proteins capable of mediating entry of the recombinant viruses into host cells. In one embodiment, a recombinant virus of the invention is a member of the Paramyx-ovirzdae family (e.g., a respiratory syncytial virus), and the heterologous envelope protein includes the ectodomain of a baculovirus envelope protein (e.g., the GP64 protein). In some cases, the heterologous envelope protein is provided in addition to homologous envelope proteins) which may or may not be functional. The heterologous protein can provide the recombinant virus with enhanced stability (e.g., at 4° C., 22° C., or 37° C.), and allows production of high-titer virus stocks. The heterologous protein can also impart temperature sensitivity to the replication of the recombinant virus. In addition, the recombinant virus can be designed to be infectious but incapable of spreading between host cells by providing the heterologous protein by complementation in trans.Type: GrantFiled: December 10, 2004Date of Patent: September 15, 2009Assignee: The UAB Research FoundationInventors: Antonius G. P. Oomens, Gail W. Wertz, Alexander George Megaw
-
Patent number: 7582289Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering a immunosuppressive agent.Type: GrantFiled: May 30, 2007Date of Patent: September 1, 2009Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Publication number: 20090214537Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.Type: ApplicationFiled: May 12, 2006Publication date: August 27, 2009Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Marco Soriani, Isabella Santi
-
Patent number: 7579004Abstract: A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed.Type: GrantFiled: November 4, 2005Date of Patent: August 25, 2009Assignee: Mayo Foundation for Medical EducationInventors: Gregory A. Poland, Inna G. Ovsyannikova, David C. Muddiman, Kenneth L. Johnson
-
Patent number: 7572904Abstract: The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described.Type: GrantFiled: March 26, 2004Date of Patent: August 11, 2009Assignee: MedImmune, LLCInventors: Xing Cheng, Hyun Jung Park, Hong Jin
-
Publication number: 20090186050Abstract: The invention relates to an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae with one or more genetic modifications. The present invention also relates to the mutant components, i.e., nucleic acids and proteins, of these mutant mammalian MPVs. These mutant mMPV can be attenuated. These mutant mMPVs can encode non-native sequences. The invention further relates to vaccine formulations comprising the mMPV, including recombinant and chimeric forms of said viruses. The vaccine preparations of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations. In addition, the invention relates to chimeric viral RNA polymerase complex and assays using these chimeric RNA polymerase complexes. The chimeric RNA polymerase complexes of the invention are composed of different RNA polymerase components from different viruses of the family of paramyxoviridae.Type: ApplicationFiled: November 14, 2008Publication date: July 23, 2009Inventors: Ron A.M. Fouchier, Sander Herfst, Miranda de Graaf
-
Publication number: 20090175902Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.Type: ApplicationFiled: June 27, 2006Publication date: July 9, 2009Inventors: Haixiang Lin, Lie Tao Victor Li
-
Patent number: 7553489Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: December 20, 2006Date of Patent: June 30, 2009Assignee: MedImmune, LLCInventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Publication number: 20090162831Abstract: The present invention relates to the discovery of a new human parvovirus, methods of detecting the parvovirus and diagnosing parvovirus infection, methods of treating or preventing parvovirus infection, and methods for identifying anti-parvoviral compounds.Type: ApplicationFiled: May 24, 2005Publication date: June 25, 2009Inventors: Eric L. Delwart, Morris S. Jones
-
Patent number: 7541038Abstract: Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.Type: GrantFiled: June 2, 2004Date of Patent: June 2, 2009Assignee: Wyeth Holdings CorporationInventors: Gerald Raul Kovacs, Xiaoyan Mo, Nikolaos Vasilakis, Sangeeta Bhargava, Timothy Joseph Zamb, Stephen Alexander Udem
-
Publication number: 20090136544Abstract: The invention relates to interfering RNAs (siRNAs, shRNAs or pre-miRNAs) directed against conserved regions of the mRNA of the N gene encoding the morbillivirus nucleoprotein. The invention also relates to the use of said interfering RNAs for the production of medicaments for use in the treatment or prevention of a morbillivirus infection.Type: ApplicationFiled: December 12, 2006Publication date: May 28, 2009Inventors: Emmanuel Albina, Genevieve Libeau, Djeneba Keita, Renata Servan De Almeida
-
Publication number: 20090123529Abstract: There is provided an immunological composition that comprises a nucleic acid vector which includes a promoter region operably linked to a coding sequence encoding the human metapneumovirus F antigen or the human metapneumovirus G antigen. The immunological composition is useful for administering to an individual to elicit an immune response to human metapneumovirus in the individual and for the generation of diagnostic reagents for hMPV.Type: ApplicationFiled: October 3, 2006Publication date: May 14, 2009Inventor: Xiaomao Li
-
Patent number: 7531342Abstract: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae , of the family Paramyxoviridae . The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences.Type: GrantFiled: February 21, 2003Date of Patent: May 12, 2009Assignees: MedImmune, LLC, ViroNovative BVInventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Aurelia Haller, Roderick Tang
-
Patent number: 7527967Abstract: Recombinant baculoviruses, virus-like particles, and polypeptide that contain a protein sequence of a heterologous virus, related compositions, and related preparation, screening, delivery, detection, and treatment methods.Type: GrantFiled: November 24, 2004Date of Patent: May 5, 2009Assignee: Academia SinicaInventors: Yu-Chan Chao, Yen-Yen Liu
-
Patent number: 7524627Abstract: The present invention relates to the Respiratory Syncytial Virus, and more particularly to the identification of novel antigens which are useful in particular for the therapeutic and prophylactic treatment of conditions caused by this virus. The present invention relates to methods of generating and/or increasing an immunogenic response directed against Respiratory Syncytial Virus, including subgroups A and B.Type: GrantFiled: November 16, 2007Date of Patent: April 28, 2009Assignee: Pierre Fabre MedicamentInventors: Nathalie Corvaia, Thien Ngoc Nguyen, Alain Beck, Hélène Plotnicky
-
Patent number: 7510863Abstract: The present invention is directed to novel avian pneumovirus strain Colorado (APV/CO) genes and intergenic sequences. Also disclosed are methods of making recombinant avian pneumovirus and live-attenuated APV/CO. Further disclosed are methods of diagnosing avian pneumovirus.Type: GrantFiled: June 16, 2004Date of Patent: March 31, 2009Assignee: University of Maryland, College ParkInventors: Siba K. Samal, Govindarajan Dhanasekaran
-
Publication number: 20090043280Abstract: The present invention relates to novel methods of vaccination and vaccine delivery.Type: ApplicationFiled: October 21, 2008Publication date: February 12, 2009Inventor: Colin Clive Dalton
-
Publication number: 20090041852Abstract: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 ?m and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation.Type: ApplicationFiled: March 15, 2007Publication date: February 12, 2009Applicant: UNIVERSITEIT GENTInventors: Jean Paul Remon, Chris Vervaet, Evy Corbanie
-
Patent number: 7485440Abstract: Recombinant respiratory syncytial virus (RSV) are provided in which expression of the second translational open reading frame encoded by the M2 gene (M2ORF2) is reduced or ablated to yield novel RSV vaccine candidates. Expression of M2 ORF2 is reduced or ablated by modifying a recombinant RSV genome or antigenome to incorporate a frame shift mutation, or one or more stop codons in M2 ORF2. Alternatively, M2 ORF2 is deleted in whole or in part to render the M2-2 protein partially or entirely non-functional or to disrupt its expression altogether. M2 ORF2 deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These changes specify one or more desired phenotypic changes in the resulting virus or subviral particle. Vaccine candidates are generated that show a change in mRNA transcription, genomic or antigenomic RNA replication, viral growth characteristics, viral antigen expression, viral plaque size, and/or a change in cytopathogenicity.Type: GrantFiled: December 13, 2004Date of Patent: February 3, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Peter L. Collins, Brian R. Murphy, Alison Bermingham
-
Publication number: 20090012494Abstract: The present invention relates to methods for intradermally delivering one or more biologically active agents such as vaccines and therapeutic agents into the dermis layer of the skin of a subject to obtain systemic delivery or an immune response using a microneedle drug delivery device containing the agent to be delivered. The methods employ a microneedle device with a row of hollow microneedles. The microneedles penetrate the skin of the subject and assume an anchored state in which the microneedles are anchored in the skin and project laterally from the device. A pivotal motion is then performed with the device so that the skin in which the microneedles are engaged is lifted above the initial plane of the surface of the skin while the biologically active agent is delivered. The methods of the invention elicit increased humoral and/or cellular response as compared to conventional vaccine delivery routes, facilitating dose sparing.Type: ApplicationFiled: November 29, 2007Publication date: January 8, 2009Applicant: NanoPass Technologies Ltd.Inventors: Yehoshua Yeshurun, Yotam Levin, Yotam Almagor, Gilad Lavi, Meir Hefetz, Yoel Sefi, Richard Ian Catchpole
-
Patent number: 7465794Abstract: Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and/or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF).Type: GrantFiled: January 8, 2004Date of Patent: December 16, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Peter L. Collins, Alexander Bukreyev, Brian R. Murphy, Stephen S. Whitehead
-
Patent number: 7442379Abstract: This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using any DNA-directed RNA polymerase such as bacteriophage T7, T3, SP6 polymerase, or eukaryotic polymerase I.Type: GrantFiled: September 16, 2002Date of Patent: October 28, 2008Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Adolfo Garcia-Sastre, Peter Palese
-
Patent number: 7442544Abstract: A method for regenerating Sendai virus particles by transfecting the Sendai virus genome to a host expressing all genes for the initial viral replication has been developed, enabling the genetic manipulation of Sendai virus and effective utilization of said virus as the vector.Type: GrantFiled: May 17, 2005Date of Patent: October 28, 2008Assignee: Dnavec Research Inc.Inventors: Yoshiyuki Nagai, Atsushi Kato, Fukashi Murai, Tsuneaki Sakata, Mamoru Hasegawa, Tatsuo Shioda
-
Publication number: 20080233148Abstract: It is intended to provide a safe and efficient method of producing a virus which is free from animal-origin components in the whole process from culturing adhesive cells to producing the virus on an industrial scale by the cell culture. Namely, a method of producing a virus comprising: adhering adhesive cells to a support which has a polypeptide (P) having at least one cell-adhesive minimum amino acid sequence (X) per molecule, and is free from animal-origin components; culturing the adhesive cells in a medium free from animal-origin components; subculturing the cultured adhesive cells using a cell dispersing agent free from animal-origin components; and then inoculating and proliferating a virus in the cells obtained by culturing the adhesive cells.Type: ApplicationFiled: July 19, 2005Publication date: September 25, 2008Applicants: Denka Seiken Co., Ltd., Sanyo Chemical Industries, Ltd.Inventors: Hikaru Kai, Masayuki Tsubaki, Masato Kurokawa
-
Publication number: 20080233150Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains RSV proteins. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing immunity to infections, including RSV.Type: ApplicationFiled: November 16, 2007Publication date: September 25, 2008Inventors: Gale SMITH, Peter Pushko, Mike Massare, Yingyun Wu, Kutub Mahmood
-
Publication number: 20080220018Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.Type: ApplicationFiled: September 4, 2007Publication date: September 11, 2008Applicant: THE ROYAL VETERINARY COLLEGEInventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
-
Publication number: 20080206281Abstract: The invention relates to methods for producing storage stable virus compositions. In certain embodiments, the invention relates to one or more formulations and process steps which result in storage stable virus compositions, wherein the composition is storage stable as a lyophilized solid composition or a frozen liquid composition.Type: ApplicationFiled: December 10, 2004Publication date: August 28, 2008Applicant: WYETHInventors: Jee Loon Look, Vladimir G. Frolov, Nandini Konar
-
Publication number: 20080181915Abstract: The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.Type: ApplicationFiled: April 4, 2008Publication date: July 31, 2008Inventors: Ralph A. Tripp, Larry J. Anderson, Michael P. Brown
-
Patent number: 7402427Abstract: The present invention provides cell fusogenic vectors having replicative ability, whose protease-dependent tropism has been modified. M gene-deficient viral vectors encoding modified F proteins, in which the cleavage site of the F protein of paramyxovirus is modified to be cleaved by different proteases, were produced. In cells transfected with these vectors, the genomic RNA present in the vectors is replicated, and cell fusogenic infection spreads to neighboring cells depending on the presence of other proteases; however, no viral particles are released. The vectors of this invention, encoding the F proteins which are cleaved by proteases whose activity is enhanced in cancer, show cancer growth suppressive effect in vivo.Type: GrantFiled: April 30, 2003Date of Patent: July 22, 2008Assignee: DNAVEC Research Inc.Inventors: Hiroaki Kinoh, Makoto Inoue, Yasuji Ueda, Akihiro Iida, Mamoru Hasegawa, Masanori Kobayashi
-
Publication number: 20080160039Abstract: The present invention relates to the use of a pneumovirus NS1 protein and/or NS2 protein or a nucleic acid encoding pneumovirus NS1 protein and/or NS2 protein for the preparation of a pharmaceutical formulation for reducing the immune response mediated by interferon (IFN). The invention further relates to recombinant pneumoviruses, in particular respiratory syncytial viruses (RSV), having an increased, reduced, or lacking a resistance to the interferon (IFN) mediated immune response, recombinant viruses having an increased resistance to the interferon (IFN) mediated immune response, and the use of the viruses in pharmaceutical applications, e.g. as vaccines.Type: ApplicationFiled: July 24, 2007Publication date: July 3, 2008Inventor: Karl-Klaus Conzelmann
-
Patent number: 7374751Abstract: Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition comprising an effective amount of IL-12 and QS-21 are also disclosed. These compositions elicit functional cell-mediated and humoral immune responses against at least one antigen. Methods of using the disclosed compositions are also disclosed.Type: GrantFiled: June 21, 2001Date of Patent: May 20, 2008Assignee: Wyeth Holdings CorporationInventor: Gerald E. Hancock
-
Patent number: 7371392Abstract: The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.Type: GrantFiled: February 2, 2001Date of Patent: May 13, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Ralph A. Tripp, Larry J. Anderson, Michael P. Brown
-
Patent number: 7364742Abstract: The present invention relates to at least one novel RSV proteins, antibodies, including isolated nucleic acids that encode at least one RSV protein or antibody, RSV vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: September 9, 2005Date of Patent: April 29, 2008Assignee: Centocor, Inc.Inventor: Bernard Scallon
-
Patent number: 7341729Abstract: The present invention relates to recombinant bovine para influenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: GrantFiled: September 3, 2004Date of Patent: March 11, 2008Assignee: MedImmune Vaccines, Inc.Inventors: Aurelia Haller, Kathleen L. Coelingh
-
Patent number: 7335366Abstract: The present invention relates i.a. to Bovine Respiratory Syncytial Viruses that are not capable of expressing a functional SH-protein and/or G-protein due to a mutation in the genes encoding the said proteins. Also the invention relates to diagnostic test kits for discriminating wild-type Bovine Respiratory Syncytial Viruses from Bovine Respiratory Syncytial Viruses according to the invention and to methods for the discrimination between those viruses.Type: GrantFiled: April 21, 2005Date of Patent: February 26, 2008Assignee: Intervet International B.V.Inventors: Ursula J. Buchholz, Ulrike Schmidt
-
Patent number: 7335361Abstract: The present invention mainly provides a fusion antigen specific for a target cell comprising a ligand moiety which is capable of reacting, recognizing or binding to the receptors on the target cell, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety which permits combination of the fusion antigen to the endoplasmic reticulum (ER) membrane of the target cell. A method of immunizing an animal using the fusion antigen is also provided.Type: GrantFiled: June 9, 2003Date of Patent: February 26, 2008Assignee: Animal Technology Institute TaiwanInventors: Chao-Wei Liao, Chung-Nan Weng
-
Patent number: 7332169Abstract: The invention relates to a process for generating infectious Newcastle disease virus (NDV) entirely from cloned full-length cDNA and to the use of vaccines and diagnostic assays generated with and derived from the process. The process offers the possibility to modify the NDV genome by means of genetic modification and allows for the introduction of mutations, deletions and/or insertions. The process can be used to modify the virulence of NDV, thus generating new attenuated live vaccines with enhanced properties. The process can be used to modify the antigenic make-up of NDV, to allow the generation of live NDV marker vaccines that can be serologically distinguished from NDV field strains.Type: GrantFiled: February 26, 2004Date of Patent: February 19, 2008Assignee: ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V.Inventors: Bernardus Petrus Hubertus Peeters, Olav Sven de Leeuw, Guus Koch, Arnoud Leonard Josef Gielkens
-
Patent number: 7323172Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: October 8, 2004Date of Patent: January 29, 2008Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Patent number: 7314631Abstract: Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting and immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen.Type: GrantFiled: December 10, 1999Date of Patent: January 1, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Brian R. Murphy, Peter L. Collins, Anna P. Durbin, Mario H. Skiadopoulos, Tao Tao
-
Patent number: 7309494Abstract: The invention concerns novel immunogenic peptides derived from the RSV G protein of the sub-group A or B comprising at least: a first peptide derived from the BRSV G protein of sub-group A or B including at least in position 173, 176, 182 and 186 a cysteine and whereof the C-terminal end includes at most the amino acid in position 192; and a second peptide derived from the RSV protein of sub-group A or B, said second peptide being located downstream of said first protein, so that the immunogenic peptide produced has a disulphide bond linking residues 173 and 186 and a second disulphide bond linking residues 176 and 182.Type: GrantFiled: July 19, 2002Date of Patent: December 18, 2007Assignee: Pierre Fabre MedicamentInventors: Nathalie Corvaia, Thien Nguyen Ngoc, Alain Beck, Hélène Plotnicky
-
Patent number: 7250171Abstract: Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome modified to encode a chimeric glycoprotein incorporating one or more heterologous antigenic domains, fragments, or epitopes of a second, antigenically distinct HPIV. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, and, optionally against respiratory syncytial virus (RSV). Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a HPIV vector genome or antigenome combined or integrated with one or more heterologous genome segment(s) encoding one or more antigenic determinant(s) of a heterologous PIV to encode a chimeric glycoprotein.Type: GrantFiled: December 10, 1999Date of Patent: July 31, 2007Assignee: United States of America as Represented by the Dept. of Health & Human ServicesInventors: Tao Tao, Mario H. Skiadopoulos, Peter L. Collins, Brian R. Murphy
-
Patent number: 7229619Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: November 28, 2000Date of Patent: June 12, 2007Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Patent number: 7223410Abstract: An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using ?-propiolactone, a non-ionic detergent, particularly n-octyl-?-D-glucopyranoside and n-octyl-?-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.Type: GrantFiled: August 5, 1994Date of Patent: May 29, 2007Assignee: Sanofi Pasteur LimitedInventors: Sonia E. Sanhueza, Mary Elizabeth Ewasyshyn, Michel Henri Klein
-
Patent number: 7223584Abstract: Live rabies virus vaccines comprising a recombinant rabies virus genome which overexpresses the rabies virus G protein increase apoptotic activity in infected cells, and enhance the generation of anti-rabies immunity in a subject.Type: GrantFiled: October 10, 2002Date of Patent: May 29, 2007Assignee: Thomas Jefferson UniversityInventors: Bernhard Dietzschold, D. Craig Hooper, Matthias J. Schnell
-
Patent number: 7208163Abstract: It was found that a mutation of an amino acid at a specific position in the P protein of a morbillivirus gives a temperature-sensitivity character to a virus. By introducing this mutation, a virus to which a temperature-sensitivity character has been introduced can be produced. According to this invention, attenuated viruses useful in the preparation of vaccines can be easily produced.Type: GrantFiled: October 18, 2000Date of Patent: April 24, 2007Assignee: The Kitasato InstituteInventors: Katsuhiro Komase, Noriko Suzuki, Tetsuo Nakayama, Chikara Aizawa
-
Patent number: 7208162Abstract: Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibodies, and an additional anti-inflammatory agent, especially corticosteroids, as well as anti-inflammatory antibodies, especially anti-interleukin-6. Also disclosed are methods of using such compositions to treat and/or prevent respiratory diseases. Such compositions may optionally contain other non-antibody anti-viral agents.Type: GrantFiled: May 3, 2001Date of Patent: April 24, 2007Assignees: MedImmune, Inc., Virion Systems, Inc.Inventors: Gregory Prince, Leslie S. Johnson
-
Patent number: 7208161Abstract: Isolated polynucleotide molecules provide recombinant PIV genomes and antigenomes for production of recombinant PIV vaccines. The recombinant genome or antigenome can be expressed with a nucleoprotein (N), phosphoprotein (P), and a large (L) polymerase protein to produce isolated infectious PIV particles. The recombinant PIV genome and antigenome can be modified to produce desired changes, for example to incorporate attenuating mutations from biologically derived PIV mutants or to create chimeric PIV clones, to generate attenuated, immunogenic viruses for vaccine use.Type: GrantFiled: May 22, 1998Date of Patent: April 24, 2007Assignee: The United States of America, represented by the Secretary, Department of Health and Human ServicesInventors: Brian R. Murphy, Peter L. Collins, Anna P. Durbin, Mario H. Skiadopoulos, Tao Tao
-
Patent number: 7205013Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: GrantFiled: October 25, 2004Date of Patent: April 17, 2007Assignee: MedImmune Vaccines, Inc.Inventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant